MetaCap

Autolus Therapeutics (AUTL) vs Scribe Therapeutics (SCTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Autolus Therapeutics is the larger company by market cap ($241.7 million vs $228.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AUTL-37.86%SCTX-36.37%
+103%+29%-45%
Jul 27, 20261 yearNov 20, 2026
AUTL-39.11%SCTX-38.04%
+81%+18%-45%
Jul 27, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AUTL versus SCTX key metrics
MetricAUTLSCTX
Share price$0.9073$12.07
Market cap$241.65M$228.58M
1-day change-7.38%-8.70%
YTD return-54.41%—
1-year return-26.24%—
5-year return-85.51%—
EPS (TTM)$-0.96$-6.35
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$75.39M—
Revenue growth (YoY)+644.94%—
Net income (latest FY)$-287.53M—
Gross margin-27.83%—
Operating margin-358.87%—
Net margin-381.40%—
52-week high$2.58$39.60
52-week low$0.896$12.00
Distance from 52-week high-64.83%-69.52%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+821.42%+372.25%
Average volume2.07M403.27K
Shares outstanding266.34M18.94M
Employees75277
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Autolus Therapeutics

AUTL stock →

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees

About Scribe Therapeutics

SCTX stock →

Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 77 employees

AUTL vs SCTX FAQ

Which is bigger, Autolus Therapeutics or Scribe Therapeutics?

Autolus Therapeutics (AUTL) is larger, with a market capitalization of $241.65M compared with $228.58M for Scribe Therapeutics (SCTX).

Are Autolus Therapeutics and Scribe Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons